FindTrial
Sign In

Evaluation of the regenerative efficacy of Endoret® (PRGF-Plasm Rich in Growth Factors) on the ocular surface of glaucoma patients treated chronically with ocular hypotensive drugs, Evaluación de la eficacia regenerativa de Endoret® (PRGF-Plasma Rico en Factores de Crecimiento) en la superficie ocular de pacientes glaucomatosos tratados de forma crónica con fármacos hipotensores oculares

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-520642-29-00
Enrollment
30
Registered
2025-01-29
Start date
Unknown
Completion date
Unknown
Last updated
2025-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glaucoma

Brief summary

Tear Osmolarity: It will be measured using the Tearlab® system (a painless collection of a 30-nanoliter tear sample using a microchip with immediate results). The difference in tear osmolarity between V0 and V2 will be evaluated. Tear osmolarity has been selected as the primary variable of the study because its increase (hyperosmolarity) has been shown to be the best standalone clinical sign for diagnosing ocular surface pathology.

Interventions

DRUGENDORET-PRGF

Sponsors

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Tear Osmolarity: It will be measured using the Tearlab® system (a painless collection of a 30-nanoliter tear sample using a microchip with immediate results). The difference in tear osmolarity between V0 and V2 will be evaluated. Tear osmolarity has been selected as the primary variable of the study because its increase (hyperosmolarity) has been shown to be the best standalone clinical sign for diagnosing ocular surface pathology.—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026